Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda
dc.contributor.author | Musinguzi, N | |
dc.contributor.author | Mocello, RA | |
dc.contributor.author | Boum, Y | |
dc.contributor.author | Hunt, PW | |
dc.contributor.author | Martin, JN | |
dc.contributor.author | Haberer, JE | |
dc.contributor.author | Bangsberg, DR | |
dc.contributor.author | Siedner, MJ | |
dc.date.accessioned | 2017-02-28T22:42:19Z | |
dc.date.available | 2017-02-28T22:42:19Z | |
dc.date.issued | 2016-06-02 | en |
dc.date.submitted | 2016-06-15 | en |
dc.identifier.citation | Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. 2016: AIDS Behav | en |
dc.identifier.issn | 1573-3254 | en |
dc.identifier.pmid | 27256394 | en |
dc.identifier.doi | 10.1007/s10461-016-1447-1 | en |
dc.identifier.uri | http://hdl.handle.net/10144/618825 | |
dc.description.abstract | Little is known about associations between viral suppression, adherence, and duration of prior viral suppression in sub-Saharan Africa. Study participants were from the UARTO study in Mbarara, Uganda. We fit regression models to characterize relationships between average adherence, treatment interruptions, and rebound viremia (>400 copies/mL) following a previously undetectable result. Our goal was to understand the impact of prior viral suppression on these relationships. 396 participants contributed 2864 quarterly visits. Restricted to periods with average adherence <50 %, each 10 % increase in adherence reduced the odds of rebound viremia by 74 % [adjusted odds ratio (AOR) = 0.26, P = 0.002] and 29 % (AOR = 0.71, P = 0.057) during the first 12 months of suppression and beyond 12 months respectively, interaction term P = 0.018. Among periods with adherence ≥50 %, the risk of rebound viremia decreased with increasing adherence during the first 12 months of viral suppression (AOR = 0.73 for each 10 % increase, P = 0.001), but not thereafter (AOR = 1.09, P = 0.67), interaction term P = 0.027. In contrast, 72-h interruptions, were associated with increased rebound viremia during the first 12 months (AOR = 1.30, P = 0.009) and after (AOR = 1.39, P = 0.005), interaction term P = 0.69. Completing 12 months of viral suppression decreases the impact of average adherence, but not prolonged treatment interruptions, on risk of rebound viremia. | |
dc.language | ENG | en |
dc.language.iso | en | en |
dc.publisher | SpringerLink We regret that this article is behind a paywall. | en |
dc.title | Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda | en |
dc.identifier.journal | AIDS and Behavior | en |
dc.internal.reviewer-note | AIDS and Behaviour - Springer pay | en |
html.description.abstract | Little is known about associations between viral suppression, adherence, and duration of prior viral suppression in sub-Saharan Africa. Study participants were from the UARTO study in Mbarara, Uganda. We fit regression models to characterize relationships between average adherence, treatment interruptions, and rebound viremia (>400 copies/mL) following a previously undetectable result. Our goal was to understand the impact of prior viral suppression on these relationships. 396 participants contributed 2864 quarterly visits. Restricted to periods with average adherence <50 %, each 10 % increase in adherence reduced the odds of rebound viremia by 74 % [adjusted odds ratio (AOR) = 0.26, P = 0.002] and 29 % (AOR = 0.71, P = 0.057) during the first 12 months of suppression and beyond 12 months respectively, interaction term P = 0.018. Among periods with adherence ≥50 %, the risk of rebound viremia decreased with increasing adherence during the first 12 months of viral suppression (AOR = 0.73 for each 10 % increase, P = 0.001), but not thereafter (AOR = 1.09, P = 0.67), interaction term P = 0.027. In contrast, 72-h interruptions, were associated with increased rebound viremia during the first 12 months (AOR = 1.30, P = 0.009) and after (AOR = 1.39, P = 0.005), interaction term P = 0.69. Completing 12 months of viral suppression decreases the impact of average adherence, but not prolonged treatment interruptions, on risk of rebound viremia. |